Michael Chudy
Overview
Explore the profile of Michael Chudy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prax M, Debes L, Chudy M, Filomena A, Pisani G, Pupella S, et al.
Vox Sang
. 2025 Feb;
PMID: 39961285
Background And Objectives: The European Directorate for the Quality of Medicines & HealthCare has been co-ordinating an external quality assessment programme for blood establishment (BE) laboratories since 2010. To further...
2.
Baylis S, Chudy M, Blumel J
Transfusion
. 2024 Feb;
64(2):416-418.
PMID: 38379531
No abstract available.
3.
Himmelsbach K, Mueller S, Kress J, Fiedler S, Miskey C, Ivics Z, et al.
Transfusion
. 2022 Dec;
63(2):339-347.
PMID: 36515262
Background: Viral safety of blood products in Germany has improved significantly over the last two decades. We describe the second documented transfusion-transmitted (TT) episode for the hepatitis C virus (HCV)...
4.
Roth H, Kress J, Chudy M, Blumel J, Schmidt-Chanasit J, Cadar D, et al.
Microbiol Resour Announc
. 2021 Oct;
10(43):e0074021.
PMID: 34709054
We report the sequences of two West Nile virus (WNV) strains (lineages 1 and 2) developed by the Paul-Ehrlich-Institut as reference materials. The materials are calibrated against the 1 World...
5.
Stelzl E, Ciesek S, Cornberg M, Maasoumy B, Heim A, Chudy M, et al.
J Clin Virol
. 2021 Aug;
142:104932.
PMID: 34333392
Objectives: Quantification of plasma hepatitis D virus (HDV) RNA is the essential tool for patient management under antiviral therapy. The aim of this European multicenter study was to improve the...
6.
Taconet L, Seifner A, Baylis S, Chudy M, KreB J, Mathys E, et al.
Biologicals
. 2021 May;
71:9-19.
PMID: 34006447
The European Directorate for the Quality of Medicines & HealthCare (EDQM) has run proficiency testing schemes on the detection of viral contaminants in human plasma pools by nucleic-acid amplification techniques...
7.
Golsaz-Shirazi F, Asadi-Asadabad S, Sarvnaz H, Amiri M, Hojjat-Farsangi M, Chudy M, et al.
Clin Chim Acta
. 2020 Jul;
510:203-210.
PMID: 32679130
Hepatitis B surface antigen (HBsAg) specific monoclonal antibodies (mAbs) are potentially valuable therapeutic and diagnostic tool. We have previously established and characterized a panel of mAbs derived from immunized BALB/c...
8.
Scheiblauer H, Heiden M, Funk M, Oberle D, Kress J, Jork C, et al.
Vox Sang
. 2020 Feb;
115(3):152-161.
PMID: 32023664
Background And Objectives: Assessment of HBV-NAT testing compared to HBsAg and anti-HBc screening in German blood establishments for the period 2008-2015. Materials And Methods: Blood donations screened for HBsAg and...
9.
Juhl D, Chudy M, Gorg S, Hennig H
Transfus Apher Sci
. 2020 Jan;
59(3):102721.
PMID: 31964608
Objective: To assess the prevalence of HDV infections in German blood donors. Method: 167 donors with acute/chronic or resolved HBV infection and detectable antibodies against Hepatitis B core antigen (anti-HBc)...
10.
Fiedler S, Oberle D, Chudy M, Scheiblauer H, Henseler O, Halbauer J, et al.
Vox Sang
. 2019 Apr;
114(5):443-450.
PMID: 31012114
Background And Objectives: In Germany, in addition to standard blood donor screening, further mandatory tests were introduced for HCV-RNA, HIV-1-RNA and for anti-HBc. Screening for HBV-DNA is optional. This study...